Polymedix to Make Multiple Presentations of New Antibiotic Data at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, will make a total of four presentations of pre-clinical data on its antibiotic compounds at the Interscience Conference on Antimicrobial Agents and Chemotherapy. The conference, held on behalf of the American Society for Microbiology (ASM) and the Infectious Diseases Society of America (IDSA), is taking place in Washington D.C. Saturday, October 25 through Tuesday, October 28, 2008.
The four presentations relating to PolyMedix’s antibiotic compounds are summarized as follows:
Membrane Disrupting Antimicrobial Peptide Mimics as Antimalarial Therapeutics, by Dr. Doron Greenbaum of the University of Pennsylvania. Slide session 229; Monday, October 27, 2:15 – 2:30 PM EST.
Earlier today, Dr. Greenbaum gave a platform slide presentation and presented for the first time data showing the activity of some of PolyMedix’s novel defensin-mimetic antibiotic compounds against the malaria parasite, Plasmodium falciparum. Dr. Greenbaum’s in vitro (test tube)
laboratory studies demonstrated the ability of several of PolyMedix’s defensin-mimetic antibiotic compounds to effectively eradicate the malaria parasite from human blood.
“We believe these findings are the first demonstration of a potential new approach to developing therapeutic treatments for malaria in many years,” commented President and CEO, Nicholas Landekic. “Malaria affects hundreds of millions of people around the world. We are very excited about this first public presentation in a major scientific forum regarding our antibiotic compounds for malaria. We believe our results establish the potential of this new approach for treating malaria. We deeply appreciate Dr. Gneenbaum’s landmark work in this area, and the opportunity to present these results at the prestigious ICAAC conference.”
In Vitro Activity of Novel Biomimetic Compounds Against Oral Candida Strains, by Dr. Gil Diamond, of the University of Medicine and Dentistry of New Jersey. Poster session 201; Monday, October 27, 11:15 AM – 12:15 PM
“We thank Dr. Diamond for his important work in demonstrating the antifungal activity of our defensin-mimetic antibiotic compounds. In addition to our ongoing work for antibacterial applications, we look forward to expanding into antifungal therapeutic applications with our compounds as soon as possible,” continued Nicholas Landekic.
In Vitro Antimicrobial Activities of a Novel Host Defense Protein Mimetic, PMX30063, Against Multiple Isolates of Staphylococci with Defined Susceptibility Phenotypes, by Dr. Richard Scott, Vice President of Research, PolyMedix, Inc. Poster session 290; Tuesday, October 28, 11:15 AM – 12:15 PM.
In Vivo Efficacy and Safety of a Novel Host Defense Protein Mimetic, PMX30063, a Candidate IV Agent to Treat Staphylococcal Infections, by Dr. Richard Scott, of PolyMedix, Inc. Poster session 290; Tuesday, October 28, 11:15 AM – 12:15 PM.
PolyMedix’s lead antibiotic product candidate, PMX-30063, with an initial planned indication to broadly treat Staph infections, including MRSA, is currently undergoing Phase I clinical testing.
About PolyMedix, Inc.
PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix’s compounds are based on biomimetics: non-peptide small molecule drugs and polymers that mimic the activity of proteins. The Company’s antibiotic compounds, including PMX-30063 – small molecule mimetics of human host-defense proteins – have a completely different mechanism of action from current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. These compounds are being developed as rapidly acting antibiotics for serious systemic and local infections. The Company plans to continue the development of polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company’s heptagonist compounds, including PMX-60056, reverse the activity of both heparin and Low Molecular Weight Heparins, with the goal of developing an antagonist drug that is safer and easier to use than currently approved therapy. The Company’s PMX-30063 antibiotic and PMX-60056 heptagonist are currently undergoing clinical testing. For more information, please visit PolyMedix on its website at www.polymedix.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and that could cause PolyMedix’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as “anticipates,”"believes,”"hopes,”"estimates,”"looks,”"expects,”"plans,”"intends”, “goals” and similar expression. Among other things, there can be no assurance that PolyMedix’s compounds will enter or successfully complete clinical testing or be granted regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is included in PolyMedix’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as may be required by applicable law or regulation.